A cancer-trial endpoint tells you what the study measured—not everything you might want to know about a drug. Overall survival measures whether participants live longer; progression-free survival measures time until progression or death under the trial’s definition; tumor response measures whether tumors meet specified response criteria. These results can inform decisions, but no single endpoint automatically establishes that people feel better, live longer, or will benefit in another cancer setting.
What is a clinical trial endpoint?
An endpoint is a measurement used to assess what happens to trial participants. A study’s result answers the question its endpoint was designed to measure. The U.S. Food and Drug Administration (FDA) distinguishes clinical outcomes—such as living longer or feeling or functioning better—from surrogate measures intended to predict a clinical outcome. FDA describes clinical outcomes as the most reliable clinical trial endpoints in its biomarkers and surrogate endpoints explainer.
The distinction matters because a measurable change in a tumor or disease marker is not automatically the same as a change in survival, symptoms, or day-to-day functioning. To interpret a result, first identify exactly what was measured, then consider what that measurement can and cannot establish.
What do the main cancer-trial endpoints measure?
FDA’s cancer-drug endpoint guidance describes commonly used measures and their possible regulatory roles. The boundaries below are about what each measure alone establishes, not a judgment that one endpoint is always better for every study.
#1 Best Overall
| Endpoint or measure | What it measures | What it can help show | What it does not establish by itself |
|---|---|---|---|
| Overall survival (OS) | Whether participants live longer | A direct survival outcome | Whether symptoms or functioning improved, or why a survival difference occurred |
| Progression-free survival (PFS) | Time from randomization until objective disease progression or death, whichever occurs first | Delay in progression or death under the trial’s definition | That participants lived longer or felt better |
| Time to progression (TTP) | Time until objective disease progression; death is not included in the endpoint definition | Timing of observed progression | A survival effect |
| Objective response rate (ORR) or tumor response | The proportion of participants meeting a defined objective response criterion | Tumor response, including shrinkage under the trial’s criteria | Longer life or improved symptoms |
| Patient-reported outcome (PRO) | A patient’s direct report of health status, symptoms, or functioning, without clinician interpretation | Effects captured by the selected patient-reported measure | Every aspect of clinical benefit or risk, independently of the study design and other evidence |
| Surrogate endpoint | A substitute measure intended to predict clinical benefit | Potential evidence of benefit in a validated or reasonably-likely context | Direct clinical benefit in every cancer, treatment, or population |
For a patient-friendly description of terms such as PFS and ORR, see FDA’s patient-friendly language for cancer clinical trials.
Does tumor shrinkage mean a cancer drug works?
Tumor shrinkage can show that a tumor responded according to the study’s specified criteria. It does not, on its own, show that patients lived longer or experienced fewer symptoms. A response measure is different from a direct clinical outcome: it records a defined change in the tumor, while survival and patient-reported measures address different questions.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
A surrogate endpoint goes a step further in interpretation: it is used as a substitute for the clinical outcome being studied because it is intended to predict that outcome. A surrogate may support a conclusion about likely benefit in a particular context, but it is not itself necessarily a direct measure of that benefit. FDA’s surrogate endpoint explainer describes this distinction.
What does progression-free survival mean—and how is it different from overall survival?
Under FDA’s definition, PFS is the time from randomization until objective progression or death, whichever comes first. TTP measures time until objective progression and does not include deaths in its endpoint definition. OS concerns whether participants live longer, making it a direct clinical outcome rather than a measure of progression.
A PFS result can provide information before an OS effect is known, but a delay in progression is not interchangeable with longer survival. How informative PFS is depends on the disease and trial context, including the setting, the magnitude of the effect, available therapies, and the treatment’s risks and benefits. FDA discusses these considerations in its 2018 cancer endpoint guidance.
What does accelerated approval based on a surrogate endpoint mean?
In the FDA’s accelerated approval pathway, a drug may be approved based on a surrogate endpoint that is reasonably likely to predict clinical benefit. That approval does not mean the anticipated clinical benefit has already been confirmed. Confirmatory studies are required to verify the expected benefit; FDA says failure to verify it can lead to regulatory action. The agency explains this obligation on its Accelerated Approval Program page.
Rank #4
Whether a particular surrogate has supported approval, or is considered potentially appropriate, depends on the defined indication and population. FDA’s surrogate endpoint table lists endpoints used as bases of approval or licensure and endpoints the agency considers potentially appropriate in specified contexts. A listing should not be generalized to every cancer or treatment.
What can patient-reported outcomes add?
A patient-reported outcome is information reported directly by the patient, without a clinician interpreting the response. Depending on the measure, it can capture symptoms, health status, or functioning from the patient’s perspective. It answers a different question from a scan-based tumor response or a survival endpoint.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
The result depends on how the trial is designed and which instrument it uses; a PRO does not independently capture every possible benefit or risk. FDA’s October 2024 guidance on core PROs in cancer clinical trials addresses trial design and instrument selection. Its November 2023 guidance on submitting PRO data covers submission of those data in cancer trials.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How should you judge an endpoint result?
Use the endpoint as one part of the evidence, and check the details that determine what the result means for the people and treatment setting under discussion:
- Endpoint definition: What event counted, when did measurement begin, and how were response or progression assessed?
- Population and setting: Which patients and cancer setting did the trial study? Evidence in one setting does not automatically establish benefit in another.
- Comparator and available therapies: What treatment was the drug compared with, and what other therapies were available in that setting?
- Magnitude and duration: How large was the observed effect, and how long did it last? A result’s meaning is not captured by the endpoint label alone.
- Other outcomes and harms: Consider survival, symptoms, functioning, and adverse effects alongside a progression or response result.
- For surrogates, confirmation: Check whether confirmatory evidence verifies the clinical benefit the surrogate was expected to predict.
Also note whether the trial examined many endpoints. Testing multiple endpoints can increase the chance of a false conclusion if multiplicity is not managed. FDA’s guidance on multiple endpoints explains the issue. For overall survival specifically, FDA published an August 2025 draft guidance; it is a draft and explicitly is not for implementation. FDA’s guidance documents generally reflect the agency’s current thinking and do not generally establish legally enforceable responsibilities, as noted on its 2018 endpoint guidance page.
What an endpoint result cannot tell you on its own
No endpoint label, taken alone, settles every question about a drug’s benefit, risk, or value. A progression or response result is not proof of longer life; a surrogate is not direct confirmation of its predicted clinical benefit; and a survival result does not by itself explain symptoms, functioning, or the reason for a difference. The soundest interpretation stays within the trial’s measured outcome and considers the population, comparison, duration, harms, and supporting evidence.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
